Proteostasis Therapeutics (PTI) Declines 29% Following Phase 2 Topline Results
Tweet Send to a Friend
Proteostasis Therapeutics (NASDAQ: PTI) declined 29% pre-open ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
